Lung Cancer

Experts discuss the importance of optimizing immunotherapy for advanced NSCLC, enhancing treatment selection and patient care.

Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.

The FDA approves a once-monthly dosing schedule for amivantamab and hyaluronidase-lpuj to optimize administration and cut down infusion times.

Amivantamab with lazertinib emerges as a promising frontline therapy for EGFR-mutated metastatic NSCLC, enhancing overall survival and treatment tolerability.

The phase 3 ADRIATIC trial demonstrates that consolidation durvalumab following concurrent chemoradiotherapy improves survival while maintaining health-related quality of life.

New research reveals circulating tumor cells can predict patient response to tarlatamab in small cell lung cancer, enhancing personalized treatment strategies.

New research reveals a gut bacteria-derived molecule that enhances lung cancer immunotherapy, potentially improving outcomes for patients with limited treatment options.

The role of cancer-associated fibroblasts in non–small cell lung cancer (NSCLC) drug resistance highlights innovative strategies to enhance treatment efficacy.

Researchers develop a novel therapy combining molecular glues and KRAS inhibitors, showing promise in treating KRAS-mutant non–small cell lung cancer.

A UK research team has pioneered a blood test using infrared technology to detect lung cancer cells, promising earlier diagnoses and personalized treatments.

FDA approves Rybrevant Faspro, a groundbreaking subcutaneous therapy for EGFR-mutated lung cancer, enhancing patient comfort and survival rates.

Pharmacists can help close the lung cancer screening gap by identifying high-risk tobacco users, increasing awareness, and connecting eligible patients to lifesaving early detection.

Expanding lung cancer screening to an age-based model significantly enhances early detection, potentially saving over 26,000 lives annually in the US.

The approval is based on results from the phase 3 DeLLphi-304 clinical trial.

The FDA accelerates approval of sevabertinib for advanced non–small cell lung cancer, showcasing promising efficacy and manageable safety in clinical trials.

Neladalkib offers durable responses and reduced side effects in TKI-pretreated patients.

Patients with non–small cell lung cancer (NSCLC) had an objective response rate of about 77%.

Although further data will be presented in 2026, lifileucel shows promise as a 1-time treatment for advanced non–small cell lung cancer (NSCLC).

Data from multiple KEYNOTE clinical trials support the sustained survival benefits of pembrolizumab in non–small cell lung cancer (NSCLC).

Emerging biomarkers and targeted therapies are reshaping the landscape of lung cancer treatment and drug development.

Advances in targeted therapies, combination approaches, and novel treatment strategies are shaping the management of drug-resistant lung cancer.

Insights from ESMO 2025 highlight advancements in non-small cell lung cancer treatment, focusing on novel therapies and molecular diagnostics.

TACTI-004 follows 2 clinical trials, TACTI-002 and INSIGHT-003, which also assessed efti with pembrolizumab in first-line treatment of non–small cell lung cancer (NSCLC).

Aumolertinib and osimertinib show similar efficacy and safety when treating patients with EGFR-mutant non–small cell lung cancer (NSCLC), providing valuable insights for treatment optimization.

The approval was based on positive efficacy and safety indications from the IMforte clinical trial of patients with extensive-stage small cell lung cancer (SCLC).